DrugPatentWatch Database Preview
Drugs in Development Information for Evobrutinib
» See Plans and Pricing
What is the development status for investigational drug Evobrutinib?
Evobrutinib is an investigational drug.
There have been 12 clinical trials for Evobrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2019.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are EMD Serono Research & Development Institute, Inc., Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, and Merck KGaA, Darmstadt, Germany.
There are five US patents protecting this investigational drug and forty-three international patents.
Summary for Evobrutinib
| US Patents | 5 |
| International Patents | 43 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 41 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-08-19) |
| Vendors | 23 |
Recent Clinical Trials for Evobrutinib
| Title | Sponsor | Phase |
|---|---|---|
| Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Effect of Hepatic Impairment on M2951 (Bruton's Tyrosine Kinase [BTK] Inhibitor) Pharmacokinetics (PK) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis | EMD Serono Research & Development Institute, Inc. | Phase 3 |
Clinical Trial Summary for Evobrutinib
Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib
US Patents for Evobrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidi- n-1-yl)-propenone | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Evobrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Evobrutinib | Australia | AU2012267491 | 2031-06-10 | Start Trial |
| Evobrutinib | Australia | AU2017235978 | 2031-06-10 | Start Trial |
| Evobrutinib | Brazil | BR112013030442 | 2031-06-10 | Start Trial |
| Evobrutinib | Canada | CA2833771 | 2031-06-10 | Start Trial |
| Evobrutinib | China | CN103814016 | 2031-06-10 | Start Trial |
| Evobrutinib | China | CN106831732 | 2031-06-10 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
